BioNexus Gene Lab (BGLC) Amortization of Deferred Charges (2022 - 2023)
BioNexus Gene Lab recorded quarterly Amortization of Deferred Charges of $2582.0 in Q3 2023, up 48.73% quarter-over-quarter from $1736.0 in Q3 2022, and up 48.73% year-over-year from $1736.0 in Q3 2022.
BioNexus Gene Lab's Amortization of Deferred Charges history runs 2 years deep, the most recent figure standing at $2582.0 for Q3 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Linde | 230.79 Bn | 226.84 Bn | 4.26 Bn |
| 2 | Chemical & Mining Co Of Chile | 127.66 Bn | 124.93 Bn | 778.60 Mn |
| 3 | Sherwin Williams | 72.51 Bn | 72.30 Bn | 2.78 Bn |
| 4 | Ecolab | 70.96 Bn | 70.34 Bn | 1.85 Bn |
| 5 | Air Products & Chemicals | 62.15 Bn | 63.70 Bn | 987.40 Mn |
| 6 | Ppg Industries | 25.04 Bn | 23.57 Bn | 1.66 Bn |
| 7 | LyondellBasell Industries | 21.62 Bn | 21.73 Bn | 701.00 Mn |
| 8 | Albemarle | 20.26 Bn | 19.42 Bn | 500.97 Mn |
| 9 | DuPont de Nemours | 19.45 Bn | 19.56 Bn | 602.00 Mn |
| 10 | BioNexus Gene Lab | 5.34 Mn | 1.38 Mn | -790.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 2,582.00 |
| Sep 30, 2023 | 2,582.00 |
| Sep 30, 2022 | 1,736.00 |
| Sep 30, 2022 | 1,736.00 |